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Abstract
Background: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-
chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under
discussion for its pathogenicity because there is no clinical report showing pathological evidence of Fabry disease
with E66Q mutation.
Case presentation: A 65-year-old Japanese female was referred to our hospital for chest discomfort on effort.
Transthoracic echocardiography showed severe left ventricular (LV) hypertrophy with LV outflow obstruction.
Maximum LV outflow pressure gradient was 87 mmHg, and Valsalva maneuver increased the pressure gradient up
to 98 mmHg. According to medical interview, one of her younger sister and a nephew died suddenly at age 42
and 36, respectively. Another younger sister also presented LV hypertrophy with outflow obstruction. Maximum LV
outflow pressure gradient was 100 mmHg, and the E66Q mutation was detected similar to the case.
Endomyocardial biopsy specimens presented vacuolation of cardiomyocytes, in which zebra bodies were detected
by electron microscopic examination. Although the enzymatic activity of GLA was within normal range, the c.
196G>C nucleotide change, which lead to the E66Q mutation of GLA gene, was detected. We initially diagnosed
her as cardiac Fabry disease based on the findings of zebra body. However, immunostaining showed few
deposition of globotriaosylceramide in left ventricular myocardium, and gene mutations in the disease genes for
hypertrophic cardiomyopathy (HCM), MYBPC3 and MYH6, were detected. Although the pathogenicity of the E66Q
mutation cannot be ruled out, hypertrophic obstructive cardiomyopathy (HOCM) was more reasonable to explain
the pathophysiology in the case.
Conclusions: This is the confusable case of HOCM with Fabry disease with the GLA E66Q mutation. We have to
take into consideration the possibility that some patients with the E66Q mutation may have similar histological
findings of Fabry disease, and should be examed the possibility for harboring gene mutations associated with HCM.
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Background
Fabry disease is caused by mutations in the α-
galactosidase A (GLA) gene, which is located in X-
chromosome coding for the lysosomal enzyme of
GLA. To date, more than 500 gene mutations have
been identified [1], and clinical manifestations are
varied based on the location of the mutation and gen-
der. Among many gene mutations, E66Q mutation is
relatively common, especially in Asian people [2]. The
E66Q mutation is thought to be a functional single-
nucleotide polymorphism and not a disease-causing
mutation, because residual enzymatic activity is rela-
tively preserved and the mutation site is distant from
the enzymatic active site [3]. Histological examination
is helpful to diagnose Fabry disease, and zebra body is
the strong evidence to suggest an accumulation of
globotriaosylceramide (Gb3). In the present paper, we
demonstrated confusable case of hypertrophic ob-
structive cardiomyopathy (HOCM) with cardiac Fabry
disease associated with the E66Q mutation.
Case presentation
A 65-year-old female was referred to our hospital with
chest discomfort on effort. On auscultation, a grade
III/VI systolic murmur at the 4th left intercostal space
was detected. Her blood pressure was 122/66 mmHg.
A chest X-ray showed cardiomegaly (cardiothoracic
ratio; 0.55) without pulmonary congestion, and an
electrocardiogram showed regular sinus rhythm, poor
R wave progression in leads V1 to V4, an inverted T
wave, and left ventricular (LV) high voltage (SV1 +
RV5 = 6.52 mV). She presented no angiokeratoma on
her skin, and had no history of acroparesthesia. A
medical interview revealed that her father, one of her
younger sisters, and a nephew died suddenly at age 58,
42, and 36, respectively (Fig. 1). Another younger sis-
ter also presented with LV hypertrophy with outflow
obstruction. Transthoracic echocardiography showed
diffuse LV hypertrophy with more than 20 mm wall
thickness and hyper contraction with LV outflow ob-
struction. The maximum LV outflow pressure gradient
was 87 mmHg, and Valsalva maneuver increased the
pressure gradient up to 98 mmHg (Fig. 2a-c). Moder-
ate mitral valve regurgitation was detected due to
systolic anterior motion of the anterior mitral leaflet.
Laboratory data displayed preserved renal function
and no proteinuria. Cardiac catheterization revealed a
systolic pressure gradient between mid LV and outflow
tract by 82 mmHg, and biopsy specimens presented
vacuolation of cardiomyocytes, which were stained by
periodic acid-Schiff (PAS) stain (Fig. 3a and b). Zebra
bodies were detected by electron microscopic examin-
ation in the cells with vacuolation (Fig. 3c and d).
Zebra body is a specific finding of Fabry disease, but is
also found in other lysosome diseases, such as
Niemann-Pick disease, Landing’s disease, Sandhoff ’s
disease, and mucopolysaccharidosis. The patient had
no clinical findings consistent with those diseases.
Cationic amphiphilic drugs, including gentamycin,
hydroxychloroquine, and amiodarone, are capable of
inducing phospholipidosis, leading to deposition of
zebra bodies in various cells [4–6], but she had not
taken any of these drugs. Although the enzymatic ac-
tivity of leukocyte GLA was within normal range
(62 nmol/mg/h), we initially diagnosed the case with
cardiac Fabry disease with the E66Q mutation based
on the histological findings. But because the distribu-
tion and the density of zebra body were much less
than typical cases of Fabry disease, we added the
immunostaining against Gb3 in the specimen of LV
myocardium. As compared to a case of typical Fabry
disease (Fig. 4a), there was few deposition of Gb3,
even in vacuolated cells (Fig. 4b). We also analyzed
plasma levels of Gb3, but it was within normal range
Fig. 1 Pedigree of the case. The numbers indicate current age or age at death
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(2.8 μg/ml). In contrast, when we analyzed the case
for mutations in the disease genes for HCM [7, 8], it
was revealed that the patient carried heterozygous
mutations of MYBPC3 (Gly1009Val) and MYH6
(Ser624del). Although both mutations were novel, they
were not found in the public sequence databases in-
cluding dbSNP [9], 1000 genomes [10], and Human
Genetic Variation database [11]. In addition, the
MYBPC3 mutation was predicted to be a disease-
causing mutation by three different in silico studies;
predicted to be disease-causing by Mutation Taster
[12], probably damaging (score 1.000) by PolyPhen-2
[13], and damaging (score 0) by SIFT [14]. As for the
MYH6 mutation, one amino acid at 624th position in
the head domain was deleted, which might be deleteri-
ous for the function of α-myosin heavy chain. How-
ever, because MYH6 is mainly expressed in the atrial
muscles and not in the ventricular muscles in human
adult hearts, pathological role of the MYH6 mutation
in cardiac hypertrophy in this case might be less
significant than the MYBPC3 mutation. From these
observations, HOCM was more reasonable to explain
the pathophysiology in the case, although the disease
modifying effect of the E66Q mutation cannot be
ruled out.
Several reports have already shown that E66Q mutation
is accompanied with LV hypertrophy and/or renal dysfunc-
tion [15, 16], but histological evidence of Fabry disease has
not yet been demonstrated. One report showed typical
findings of classic-type Fabry disease with E66Q mutation,
but the patient also had another R112C mutation [17]. In
the present case, both PAS-positive vacuolated cardiomyo-
cytes and small number of zebra bodies were observed in
LV myocardium, but no accumulation of Gb3, indicating
that those histological changes were not associated with
Fabry disease. A recent study showed that the frequency of
the E66Q allele was not different between hemodialysis
patients and the general Japanese population [18]. There-
fore, thorough genetic analysis is needed to perform differ-
ential diagnosis of Fabry disease. Although E66Q is
considered as functional polymorphism, not pathogenic
mutation, Nakamura et al. showed that the frequency of
the E66Q mutation was significantly higher in patients with
cerebral small vessel occlusion [19]. Thus, we need to accu-
mulate the clinical data of patients with E66Q mutation in
order to elucidate the pathological roles of E66Q mutation.
Fig. 2 Echocardiographic findings. a, b Echocardiographic images of para-sternal long axis view of LV showing diffuse cardiac hypertrophy at diastolic
(a) and systolic (b) phases. Systolic anterior motion of anterior mitral leaflet was observed. c Measurement of the pressure gradient between mid-LV
and LV outflow tract
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Conclusions
This is the confusable case of HOCM with Fabry disease.
We have to take into consideration the possibility that
some patients with the E66Q mutation may have similar
histological findings of Fabry disease, and should be ex-
amined the possibility for harboring HCM-related gene
mutations.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor of this journal. The study was approved
by the Ethics Committee of the Fukushima Medical
University School of Medicine.
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Fig. 4 Immunostaining of myocardium against Gb3. a Immunostaining of myocardium in typical Fabry disease’s case. Brown staining indicates
Gb3 accumulation. Bar, 50 μm. b Immunostaining of myocardium in the present case. Bar, 50 μm
A B
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Fig. 3 Histological findings of left ventricular endomyocardial biopsy. a Vacuolated cardiomyocytes in the left ventricle (hematoxylin and eosin
staining). Bar, 50 μm. b PAS stain-positive cardiomyocytes with vacuolation. Bar, 50 μm. c Zebra body in vacuolated cardiomyocytes. d Magnified
image of C
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